Joshua Jay Reicher
Research Subjects
Joshua Jay Reicher has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Michael Muelly
Imvaria Inc., Berkeley, CA, United States
6 shared publications - Angad Kalra
Imvaria, Inc., Berkely, CA
5 shared publications Angad Kalra
IMVARIA Inc., 1748 Shattuck Ave Pmb 137, Berkeley, 94709, CA, USA
4 shared publications- Michael Muelly
Imvaria, Inc., Berkely, CA
4 shared publications - Daniel Tse
Google Health, Palo Alto, USA
2 shared publications - Gavin Duggan
Google Health, Mountain View, USA
2 shared publications
Latest Publications
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 33 (4)
Risk Stratification of Incidental Pulmonary Nodules
Background: Incidental detection is the most common pathway through which pulmonary nodules are identified. With the advancement of navigational and robotic-assisted bronchoscopy, existing risk stratification models often lack sufficient discrimination power, particularly for intermediate-risk nodules. Bronchosolve is a fully automated, imaging-only risk stratification tool that was previously validated in lung cancer screening cohorts. Methods: We applied Bronchosolve to a cohort of adults with incidentally detected pulmonary nodules identified from registries at 2 large health care systems between 2006 and 2019. Nodules were classified as malignant or benign based on biopsy or extended clinical follow-up. Discrimination was assessed and compared with the VA Model. Sensitivity and specificity were reported at the Youden and high-sensitivity operating points. Additional analysis was performed in cases with nodule diameter 8 to 15 mm. Results: Among 187 patients, malignancy prevalence was 70%. Bronchosolve achieved an AUC of 0.895 versus 0.870 for the VA model. Among nodules 8 to 15 mm, discrimination differences were larger (AUC 0.808 vs. 0.701). In nodules of 8 to 15 mm in diameter with an intermediate risk for malignancy by the VA model, Bronchosolve reclassified 51 patients to high risk and 23 to low risk; 33/37 (89%) malignancies were up-classified and 19/37 (51%) benign nodules were down-classified. Conclusion: In a nonscreening setting, Bronchosolve demonstrated robust discrimination for lung nodule malignancy risk using imaging alone compared with a widely used clinical risk model, with more pronounced separation in intermediate-sized nodules. In this subgroup, Bronchosolve also yielded clinically meaningful risk reclassification, with potential implications for downstream management.
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 33 (4)
Risk Stratification of Incidental Pulmonary Nodules
Background: Incidental detection is the most common pathway through which pulmonary nodules are identified. With the advancement of navigational and robotic-assisted bronchoscopy, existing risk stratification models often lack sufficient discrimination power, particularly for intermediate-risk nodules. Bronchosolve is a fully automated, imaging-only risk stratification tool that was previously validated in lung cancer screening cohorts. Methods: We applied Bronchosolve to a cohort of adults with incidentally detected pulmonary nodules identified from registries at 2 large health care systems between 2006 and 2019. Nodules were classified as malignant or benign based on biopsy or extended clinical follow-up. Discrimination was assessed and compared with the VA Model. Sensitivity and specificity were reported at the Youden and high-sensitivity operating points. Additional analysis was performed in cases with nodule diameter 8 to 15 mm. Results: Among 187 patients, malignancy prevalence was 70%. Bronchosolve achieved an AUC of 0.895 versus 0.870 for the VA model. Among nodules 8 to 15 mm, discrimination differences were larger (AUC 0.808 vs. 0.701). In nodules of 8 to 15 mm in diameter with an intermediate risk for malignancy by the VA model, Bronchosolve reclassified 51 patients to high risk and 23 to low risk; 33/37 (89%) malignancies were up-classified and 19/37 (51%) benign nodules were down-classified. Conclusion: In a nonscreening setting, Bronchosolve demonstrated robust discrimination for lung nodule malignancy risk using imaging alone compared with a widely used clinical risk model, with more pronounced separation in intermediate-sized nodules. In this subgroup, Bronchosolve also yielded clinically meaningful risk reclassification, with potential implications for downstream management.
- Open Access
- 30 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2398
Paired Validation of a Multimodal Vision-Transformer System for the Non-Invasive Diagnosis of Idiopathic Pulmonary Fibrosis
Background/Objectives: Distinguishing idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases is prognostically and therapeutically important. We developed Fibresolve, a machine learning system that analyzes chest computed tomography (CT) to support IPF diagnosis. Fibresolve version 1 (v1) was validated in the PUFAIR study, met its co-primary endpoints, and received U.S. FDA authorization. Fibresolve version 2 (v2) was subsequently developed under the FDA’s Predetermined Change Control Plan (PCCP) framework and, here, is evaluated against the authorized v1 model. Methods: v2 augments the original CT-only v1 classifier by incorporating age, sex, and forced vital capacity into an ensemble, while retaining the v1 CT-only model as a fallback when these variables are unavailable. Both models were evaluated in the same 300-patient PUFAIR cohort (83 IPF, 217 non-IPF) from two U.S. centers. Reference-standard diagnoses were established by institutional multidisciplinary discussion and supported by surgical pathology in 94.7% of cases. McNemar test, Cohen , and bootstrap noninferiority analyses were used for paired model comparisons. Results: In the key thin-slice diagnostic CT subgroup (N = 137), v2 achieved a sensitivity of 57.5% (95% CI, 42.2–71.5) and specificity of 84.5% (95% CI, 76.0–90.4), compared with 55.0% (95% CI, 39.8–69.3) and 82.5% (95% CI, 73.7–88.8) for v1. Performance improvements were directionally consistent across most subgroups, with no evidence of inferior performance. Conclusions: Fibresolve v2 preserved the performance of the FDA-authorized v1 model while providing modest, directionally favorable improvements. These findings support v2 as the primary model, with v1 retained as a robust fallback when clinical variables are unavailable.- 30 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2398
Open AccessPaired Validation of a Multimodal Vision-Transformer System for the Non-Invasive Diagnosis of Idiopathic Pulmonary Fibrosis
Background/Objectives: Distinguishing idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases is prognostically and therapeutically important. We developed Fibresolve, a machine learning system that analyzes chest computed tomography (CT) to support IPF diagnosis. Fibresolve version 1 (v1) was validated in the PUFAIR study, met its co-primary endpoints, and received U.S. FDA authorization. Fibresolve version 2 (v2) was subsequently developed under the FDA’s Predetermined Change Control Plan (PCCP) framework and, here, is evaluated against the authorized v1 model. Methods: v2 augments the original CT-only v1 classifier by incorporating age, sex, and forced vital capacity into an ensemble, while retaining the v1 CT-only model as a fallback when these variables are unavailable. Both models were evaluated in the same 300-patient PUFAIR cohort (83 IPF, 217 non-IPF) from two U.S. centers. Reference-standard diagnoses were established by institutional multidisciplinary discussion and supported by surgical pathology in 94.7% of cases. McNemar test, Cohen , and bootstrap noninferiority analyses were used for paired model comparisons. Results: In the key thin-slice diagnostic CT subgroup (N = 137), v2 achieved a sensitivity of 57.5% (95% CI, 42.2–71.5) and specificity of 84.5% (95% CI, 76.0–90.4), compared with 55.0% (95% CI, 39.8–69.3) and 82.5% (95% CI, 73.7–88.8) for v1. Performance improvements were directionally consistent across most subgroups, with no evidence of inferior performance. Conclusions: Fibresolve v2 preserved the performance of the FDA-authorized v1 model while providing modest, directionally favorable improvements. These findings support v2 as the primary model, with v1 retained as a robust fallback when clinical variables are unavailable. - 20 January 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101373
Performance validation of a closed loop fully automated AI model for lung nodule stratification in screening cases
- 20 January 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101373
Performance validation of a closed loop fully automated AI model for lung nodule stratification in screening cases
- 27 November 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 250, 108545
Automated artificial intelligence detection of early or under-diagnosed interstitial lung disease by computed tomography in the COPDGene trial
- 27 November 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 250, 108545
Automated artificial intelligence detection of early or under-diagnosed interstitial lung disease by computed tomography in the COPDGene trial
- 6 August 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (5) , 1012-1017
Multi-modal machine learning classifier for idiopathic pulmonary fibrosis predicts mortality in interstitial lung diseases
- 6 August 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (5) , 1012-1017
Multi-modal machine learning classifier for idiopathic pulmonary fibrosis predicts mortality in interstitial lung diseases
- 27 February 2025
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 369 (6) , 705-711
ScreenDx, an artificial intelligence-based algorithm for the incidental detection of pulmonary fibrosis
- 27 February 2025
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 369 (6) , 705-711
ScreenDx, an artificial intelligence-based algorithm for the incidental detection of pulmonary fibrosis
- 20 May 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (4) , 670-676
Computed tomography machine learning classifier correlates with mortality in interstitial lung disease
- 20 May 2024
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (4) , 670-676
Computed tomography machine learning classifier correlates with mortality in interstitial lung disease
- Open Access
- 17 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (8) , 830
A Machine Learning System to Indicate Diagnosis of Idiopathic Pulmonary Fibrosis Non-Invasively in Challenging Cases
Radiologic usual interstitial pneumonia (UIP) patterns and concordant clinical characteristics define a diagnosis of idiopathic pulmonary fibrosis (IPF). However, limited expert access and high inter-clinician variability challenge early and pre-invasive diagnostic sensitivity and differentiation of IPF from other interstitial lung diseases (ILDs). We investigated a machine learning-driven software system, Fibresolve, to indicate IPF diagnosis in a heterogeneous group of 300 patients with interstitial lung disease work-up in a retrospective analysis of previously and prospectively collected registry data from two US clinical sites. Fibresolve analyzed cases at the initial pre-invasive assessment. An Expert Clinical Panel (ECP) and three panels of clinicians with varying experience analyzed the cases for comparison. Ground Truth was defined by separate multi-disciplinary discussion (MDD) with the benefit of surgical pathology results and follow-up. Fibresolve met both pre-specified co-primary endpoints of sensitivity superior to ECP and significantly greater specificity (p = 0.0007) than the non-inferior boundary of 80.0%. In the key subgroup of cases with thin-slice CT and atypical UIP patterns (n = 124), Fibresolve’s diagnostic yield was 53.1% [CI: 41.3–64.9] (versus 0% pre-invasive clinician diagnostic yield in this group), and its specificity was 85.9% [CI: 76.7–92.6%]. Overall, Fibresolve was found to increase the sensitivity and diagnostic yield for IPF among cases of patients undergoing ILD work-up. These results demonstrate that in combination with standard clinical assessment, Fibresolve may serve as an adjunct in the diagnosis of IPF in a pre-invasive setting.
- 17 April 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (8) , 830
Open AccessA Machine Learning System to Indicate Diagnosis of Idiopathic Pulmonary Fibrosis Non-Invasively in Challenging Cases
Radiologic usual interstitial pneumonia (UIP) patterns and concordant clinical characteristics define a diagnosis of idiopathic pulmonary fibrosis (IPF). However, limited expert access and high inter-clinician variability challenge early and pre-invasive diagnostic sensitivity and differentiation of IPF from other interstitial lung diseases (ILDs). We investigated a machine learning-driven software system, Fibresolve, to indicate IPF diagnosis in a heterogeneous group of 300 patients with interstitial lung disease work-up in a retrospective analysis of previously and prospectively collected registry data from two US clinical sites. Fibresolve analyzed cases at the initial pre-invasive assessment. An Expert Clinical Panel (ECP) and three panels of clinicians with varying experience analyzed the cases for comparison. Ground Truth was defined by separate multi-disciplinary discussion (MDD) with the benefit of surgical pathology results and follow-up. Fibresolve met both pre-specified co-primary endpoints of sensitivity superior to ECP and significantly greater specificity (p = 0.0007) than the non-inferior boundary of 80.0%. In the key subgroup of cases with thin-slice CT and atypical UIP patterns (n = 124), Fibresolve’s diagnostic yield was 53.1% [CI: 41.3–64.9] (versus 0% pre-invasive clinician diagnostic yield in this group), and its specificity was 85.9% [CI: 76.7–92.6%]. Overall, Fibresolve was found to increase the sensitivity and diagnostic yield for IPF among cases of patients undergoing ILD work-up. These results demonstrate that in combination with standard clinical assessment, Fibresolve may serve as an adjunct in the diagnosis of IPF in a pre-invasive setting.
- 11 January 2024
- Published by Springer Nature in Journal of Imaging Informatics in Medicine
- Vol. 37 (1) , 297-307
Analysis of Validation Performance of a Machine Learning Classifier in Interstitial Lung Disease Cases Without Definite or Probable Usual Interstitial Pneumonia Pattern on CT Using Clinical and Pathology-Supported Diagnostic Labels
We previously validated Fibresolve, a machine learning classifier system that non-invasively predicts idiopathic pulmonary fibrosis (IPF) diagnosis. The system incorporates an automated deep learning algorithm that analyzes chest computed tomography (CT) imaging to assess for features associated with idiopathic pulmonary fibrosis. Here, we assess performance in assessment of patterns beyond those that are characteristic features of usual interstitial pneumonia (UIP) pattern. The machine learning classifier was previously developed and validated using standard training, validation, and test sets, with clinical plus pathologically determined ground truth. The multi-site 295-patient validation dataset was used for focused subgroup analysis in this investigation to evaluate the classifier’s performance range in cases with and without radiologic UIP and probable UIP designations. Radiologic assessment of specific features for UIP including the presence and distribution of reticulation, ground glass, bronchiectasis, and honeycombing was used for assignment of radiologic pattern. Output from the classifier was assessed within various UIP subgroups. The machine learning classifier was able to classify cases not meeting the criteria for UIP or probable UIP as IPF with estimated sensitivity of 56–65% and estimated specificity of 92–94%. Example cases demonstrated non-basilar-predominant as well as ground glass patterns that were indeterminate for UIP by subjective imaging criteria but for which the classifier system was able to correctly identify the case as IPF as confirmed by multidisciplinary discussion generally inclusive of histopathology. The machine learning classifier Fibresolve may be helpful in the diagnosis of IPF in cases without radiological UIP and probable UIP patterns.
- 11 January 2024
- Published by Springer Nature in Journal of Imaging Informatics in Medicine
- Vol. 37 (1) , 297-307
Analysis of Validation Performance of a Machine Learning Classifier in Interstitial Lung Disease Cases Without Definite or Probable Usual Interstitial Pneumonia Pattern on CT Using Clinical and Pathology-Supported Diagnostic Labels
We previously validated Fibresolve, a machine learning classifier system that non-invasively predicts idiopathic pulmonary fibrosis (IPF) diagnosis. The system incorporates an automated deep learning algorithm that analyzes chest computed tomography (CT) imaging to assess for features associated with idiopathic pulmonary fibrosis. Here, we assess performance in assessment of patterns beyond those that are characteristic features of usual interstitial pneumonia (UIP) pattern. The machine learning classifier was previously developed and validated using standard training, validation, and test sets, with clinical plus pathologically determined ground truth. The multi-site 295-patient validation dataset was used for focused subgroup analysis in this investigation to evaluate the classifier’s performance range in cases with and without radiologic UIP and probable UIP designations. Radiologic assessment of specific features for UIP including the presence and distribution of reticulation, ground glass, bronchiectasis, and honeycombing was used for assignment of radiologic pattern. Output from the classifier was assessed within various UIP subgroups. The machine learning classifier was able to classify cases not meeting the criteria for UIP or probable UIP as IPF with estimated sensitivity of 56–65% and estimated specificity of 92–94%. Example cases demonstrated non-basilar-predominant as well as ground glass patterns that were indeterminate for UIP by subjective imaging criteria but for which the classifier system was able to correctly identify the case as IPF as confirmed by multidisciplinary discussion generally inclusive of histopathology. The machine learning classifier Fibresolve may be helpful in the diagnosis of IPF in cases without radiological UIP and probable UIP patterns.
- 24 December 2023
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 367 (3) , 195-200
External validation of Fibresolve, a machine-learning algorithm, to non-invasively diagnose idiopathic pulmonary fibrosis
- 24 December 2023
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 367 (3) , 195-200
External validation of Fibresolve, a machine-learning algorithm, to non-invasively diagnose idiopathic pulmonary fibrosis